5,535 Shares in Biohaven Ltd. (NYSE:BHVN) Bought by HighTower Advisors LLC

HighTower Advisors LLC purchased a new position in shares of Biohaven Ltd. (NYSE:BHVN) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 5,535 shares of the company’s stock, valued at approximately $276,000.

Other institutional investors have also modified their holdings of the company. SpiderRock Advisors LLC purchased a new stake in shares of Biohaven during the third quarter worth approximately $620,000. Citigroup Inc. increased its position in Biohaven by 125.8% during the third quarter. Citigroup Inc. now owns 119,905 shares of the company’s stock worth $5,992,000 after buying an additional 66,801 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in Biohaven by 234.5% in the 2nd quarter. Principal Financial Group Inc. now owns 79,048 shares of the company’s stock valued at $2,744,000 after purchasing an additional 55,415 shares in the last quarter. Cadent Capital Advisors LLC purchased a new stake in Biohaven in the 3rd quarter worth approximately $1,771,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Biohaven by 563.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 508,622 shares of the company’s stock valued at $25,416,000 after purchasing an additional 431,954 shares during the last quarter. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on BHVN. William Blair upgraded Biohaven to a “strong-buy” rating in a report on Friday, August 30th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $61.00 target price (up from $58.00) on shares of Biohaven in a research report on Wednesday, December 4th. Leerink Partners raised their price objective on shares of Biohaven from $55.00 to $60.00 and gave the stock an “outperform” rating in a report on Monday, September 23rd. TD Cowen increased their target price on shares of Biohaven from $55.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, JPMorgan Chase & Co. upped their price target on shares of Biohaven from $55.00 to $68.00 and gave the stock an “overweight” rating in a research report on Thursday, October 3rd. Thirteen equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $63.00.

Biohaven Trading Down 0.3 %

Shares of NYSE BHVN opened at $36.15 on Tuesday. The firm has a 50-day moving average of $46.88 and a two-hundred day moving average of $41.95. The company has a market capitalization of $3.66 billion, a price-to-earnings ratio of -3.87 and a beta of 1.24. Biohaven Ltd. has a twelve month low of $26.80 and a twelve month high of $62.21.

Biohaven (NYSE:BHVN) last issued its earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.03). As a group, research analysts predict that Biohaven Ltd. will post -8.85 earnings per share for the current year.

Insider Transactions at Biohaven

In related news, Director John W. Childs acquired 21,052 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were purchased at an average price of $47.50 per share, for a total transaction of $999,970.00. Following the acquisition, the director now owns 21,052 shares in the company, valued at approximately $999,970. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 16.00% of the company’s stock.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.